Speakers: 

Jonathan "Ryan" Lozano, PharmD, PGY2 Oncology Resident, Geisinger - has nothing to disclose.

Dominick Patafio, PharmD, PGY2 Oncology Resident, Geisinger - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Pharmacy Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

It’s Not Always Sunny in Philadelphia: The Results of PhALLCON

• Describe the epidemiology and survival statistics of acute lymphoblastic leukemia (ALL)
• Characterize the Philadelphia Chromosome (Ph) and its presence in ALL
• Evaluate current literature surrounding the use of BCR-ABL TKIs in Ph+ ALL
• Compare the efficacy and safety of ponatinib and imatinib in combination with low-intensity chemotherapy for Ph+ ALL

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer (DeLLphi-301)

• Summarize background on small-cell lung cancer & treatments
• Describe BiTE therapy & pharmacology of tarlatamab
• Discuss key components of DeLLphi-301 trial
• Assess important findings from DeLLphi-301 trial
• Apply findings to guidelines and clinical practice
   

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session

None.